Cancer drug developer BlossomHill slips post IPO (BLSM:NASDAQ)
· seekingalpha.com
BlossomHill Therapeutics (BLSM) stock dips on trading debut after an upsized initial public offering that raised the cancer drug developer $150M. Read more here.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...